As the most common genetic neurological disease contributing to infant mortality, researchers have been exploring the utility of autologous stem cell therapies (or therapies that use a patient’s own stem cells) in treating Spinal muscular atrophy (SMA).
Transplanted neural stem cells (shown here) were used to treat a mouse model of ALS. (Credit: Sanford-Burnham Medical Research Institute)
A consortium of researchers have successfully demonstrated that the transplantation of neural stem cells in the spinal cord of an ALS mouse model can slow the disease onset and progression, as well as improve motor function and significantly prolong the lifetime of the diseased agent.
StemSave Scientific Advisor Dr. George T.-J. Huang, Director of Stem Cells and Regenerative Therapies at the University of Tennessee Health Science Center, was awarded $1.8 million from The National Institute of Dental and Craniofacial Research, to continue his research pertaining to stem cell based regenerative root canal treatments.
Mesoblast, a leading stem cell technology and regenerative therapeutics company, received FDA approval to begin a Phase III clinical trial utilizing their stem cell therapy [Revascor] to treat heart failure. We have reported on Mesoblast in previous posts; most recently, the announcement that they were developing neural related regenerative therapies utilizing dental pulp stem cells.